TL;DR
Nursing home operators say more residents are arriving on GLP-1 medications, with one provider reporting use among 30% to 40% of new admissions. Clinicians are adding monitoring and staff education, while a temporary Medicare coverage program leaves residents and facilities facing out-of-pocket and reimbursement questions.
GLP-1 medications are increasingly arriving with nursing home residents, prompting operators to expand clinical monitoring while weighing the drugs’ cost and coverage, according to a report published by Skilled Nursing News. Venza Care chief nursing officer Lisa Chubb said about 30% to 40% of the company’s newly admitted residents use a GLP-1, a trend that brings new questions about nutrition, frailty and who pays for treatment.
Chubb said residents are taking the medications not only for diabetes and weight loss, but also for purposes related to cardiovascular health, metabolic conditions and organ health. The reported share of new admissions on GLP-1s is higher at facilities with more short-stay residents, she said. The figures describe Venza Care’s admissions and are not a national estimate.
At Venza, interdisciplinary teams hold weekly “nutrition at risk” meetings, use electronic health record assessments to document medication review and education, and monitor residents’ weight. Registered dietitians are involved in care, Chubb said. The extra oversight reflects concern that weight loss may aggravate muscle weakness or frailty in some older adults, even when treatment is intended to address other health risks.
Payment depends on the resident’s coverage and circumstances. Jessie McGill of the American Association for Post-Acute Care Nursing said a Medicare Part D bridge program covers certain GLP-1s prescribed for weight loss, subject to eligibility, with a $50 monthly fee in addition to Part D coverage. McGill said the eligible drugs are Wegovy, Zepbound and Foundeo. For some residents, including people with limited means, that fee can remain a barrier. If a resident is covered under Medicare Part A in a nursing home, the facility may be responsible for the medication cost, McGill said.
Care Teams Face New Monitoring Demands
Wider use of these medications could affect day-to-day nursing home care, from nutrition assessments and weight monitoring to staff training and facility quality programs. The clinical balance is not straightforward: providers may see potential health benefits, but older residents can have existing frailty, nutritional risks and functional limitations that make weight loss consequential.
Costs may also shape access and facility decisions. Journey Skilled Nursing chief nursing officer Jody O’Mara said high-cost drugs become an operational concern when a provider is responsible for pharmacy expenses. If coverage is limited or a medication falls outside the bridge program, a resident’s treatment may carry costs for the individual or the facility. The report does not establish how widespread these payment pressures are across nursing homes.
Temporary Coverage Leaves a Gap
Medicare’s bridge program provides temporary coverage for eligible residents with Part D, while the more permanent BALANCE program has been delayed without a new implementation date, according to the report. The bridge program has been extended through 2027. Eligibility depends on factors including the drug and the resident’s clinical profile; it does not cover every GLP-1 prescription.
McGill said nursing homes may have to account for medication expenses when a resident enters on a GLP-1 that is not covered through the bridge program. She identified expanding Medicare consolidated billing to include high-cost drugs such as GLP-1s as a possible policy change, but that would require congressional action. The source report offers no indication that such an expansion has been approved.
“We see a lot of our new admissions coming in with GLP-1s.”
— Lisa Chubb, chief nursing officer for Venza Care
Coverage and Clinical Risks Vary
The report does not provide national data on how many nursing home residents use GLP-1s, nor does it establish how often the medications improve outcomes in this population. Venza’s admission figures are specific to that operator. The source also does not quantify the total cost to facilities or residents, or say how many people cannot afford the monthly bridge-program fee.
Clinical suitability will differ among residents. The report identifies potential concerns including frailty, nutritional status and side effects, but does not give comparative outcome data or detailed guidance for individual treatment decisions. The future start date and final terms of BALANCE remain unknown.
Bridge Coverage Runs Through 2027
The Medicare bridge program is scheduled to continue through 2027, while a permanent coverage approach remains pending. Nursing home operators will need to continue reviewing residents’ prescriptions, coverage eligibility and any facility responsibility for drug costs as admissions rise.
Further developments to watch include whether CMS sets a new timeline for BALANCE and whether Congress considers changes to consolidated billing. Providers’ experience with monitoring, staffing and medication expenses may also clarify how GLP-1 use affects nursing home care, but the report does not identify a specific next policy decision or deadline.
Key Questions
How common are GLP-1s among nursing home residents?
Venza Care’s Lisa Chubb said 30% to 40% of the operator’s new admissions are on GLP-1s, with higher shares at facilities that have more short-stay residents. This is not a national estimate.
Which GLP-1s are included in the Medicare bridge program?
AAPACN’s Jessie McGill said the bridge program covers Wegovy, Zepbound and Foundeo for eligible residents under specified conditions. The report says residents may also face a $50 monthly fee alongside Part D coverage.
Who pays for a resident’s GLP-1 in a nursing home?
Payment varies with the resident’s Medicare coverage, eligibility and drug. McGill said a facility may be responsible for the cost for residents on Medicare Part A; some prescriptions may instead receive Part D coverage through the bridge program.
What clinical issues are nursing homes monitoring?
Operators described monitoring weight and nutrition and educating care teams. The report also cites concerns about frailty, muscle weakness, nausea, vomiting, constipation and dehydration. Treatment decisions depend on each resident’s situation.
Source: skillednursingnews.com
